October 2, 2009
Speakers

Introduction
Dr. Laura Shawver, Founder – The Clearity Foundation

Dr. Shawver considers herself lucky. Three years out from an ovarian cancer diagnosis when most women are battling a recurrence, she continues as CEO of Phenomix Corp, works diligently to bring molecular profiling to other ovarian cancer patients and surfs most mornings near her home in San Diego. While The Clearity Foundation is focused on bringing molecular profiling to the forefront of ovarian cancer treatment, especially for recurrent and refractory patients, the efforts can be applied to all types of difficult cancers and hence the idea for this educational event. Many cancer patients and their doctors are not aware that there are resources TODAY that may be able to better define their treatments either as off-label use or in a clinical trial. Who can benefit, how is it done and who pays for it are all important questions in the quest for personalized medicine in cancer treatment.

Dr. Shawver received her Ph.D. in pharmacology in 1984 from the University of Iowa. After post-doctoral fellowships, she began a career in biotech in 1989 at Triton Biosciences. Prior to Phenomix where she is CEO, Dr. Shawver was President of SUGEN, Inc after holding several previous positions there. Currently, she serves as Deputy Editor of Molecular Cancer Therapeutics, serves on the Science Policy and Legislative Affairs Committee for the American Association for Cancer Research and on their Scientific Advisory Committee for Stand Up 2 Cancer. Dr. Shawver also serves on the Biotechnology Industry Organization board.

The Patient's Perspective
Christy Conroy-Lucio, Esq

A lawyer employed by the Santa Clara County Public Defender's Office, Christy Conroy-Lucio has been battling ovarian cancer since 2002. Originally diagnosed with Stage 2b and after surgery and standard-of-care carboplatin/taxol regimen, she first recurred in 2005. Following remission again after a second course of carboplatin/taxol, she recurred a short time later and has been treated with Topotecan, Doxil, Gemzar and various combinations. She has had several surgeries including one in 2007 for lung metastases. After successful treatment with Abraxane in late 2008 through August 2009 when her CA125 (a blood marker that is used in ovarian cancer as a surrogate marker for extent of disease) dropped from >8000 to 10, Christy continues her quest for a drug that might finally cure her disease.

Personalized Treatments Today with TargetNow
Dr. Stephen Anthony, Evergreen Hematology and Oncology
Senior Investigator, TGen

Dr. Anthony is known in the cancer research field and has published and lectured in the area of understanding cancer drug resistance, breast cancer and solid tumor therapy, and the application of new genomic technologies for drug development and treatment of oncology patients in a more targeted fashion.

Dr. Anthony continues to do research as a Senior Investigator for the Translational Genomics Research Institute (TGen), a nonprofit biotechnical institute where he has two funded clinical research projects. He continues to serve as the Chief Medical Officer for The Translational Drug Development (TD2) Division of TGen.

Dr. Anthony sees patients four days a week which allows him to understand the clinical and practical issues of managing patients. He actively participates in clinical trials from Phase I to Phase III. After working at TGen for two years full-time he moved back to the Pacific NW to accommodate his family but also to bring back new molecular techniques critical to treating patients today. His fundamental training in molecular oncology begun at Dartmouth Medical School 15 years ago remains strongly alive in his passion of guiding new drug development as well as seeing patients.

Developing Molecular Targeted Agents Through Translational Medicine – The Clinical Trial Perspective
Dr. Rich Buller, Vice President Translational Medicine, Exelixis

Dr. Buller has held the position of Vice President, Translational Medicine at Exelixis for the past two and a half years where his group plays a central role in relating cancer drug effects in patients to drug targets and host genetics. Prior to joining Exelixis, he was a Director in the Oncology Medicine Development Centre at GlaxoSmithKline (GSK) for four years focusing on development and implementation of clinical strategies around the company's portfolio of oncology drug candidates. At GSK, he co-led the successful registration of topotecan for the treatment of cervical cancer. Previously, Dr. Buller was Professor, Departments of Obstetrics and Gynecology and Pharmacology at the University of Iowa College of Medicine. He received a BS in chemistry from UCLA and was awarded both the Doctor of Medicine and Doctor of Philosophy degrees from Baylor College of Medicine before completing a residency in the Department of OB/GYN & Reproductive Medicine at the University of California, San Francisco and a fellowship in gynecologic oncology at the University of California, Irvine. Dr Buller is a board certified gynecologic oncologist with extensive clinical trials experience as Co-Principal Investigator, Gynecologic Oncology Group while at Iowa. His major laboratory research interest over the years has been the molecular genetics of ovarian cancer.

Breaking through chemoresistance
Dr. Lorianne Masuoka, Chief Medical Officer, Nektar Therapeutics

Dr. Masuoka joined Nektar in August 2008 and has over 15 years of experience in clinical research and development. Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. NKTR-102 is a novel form of irinotecan developed using Nektar's advanced polymer conjugate technology. Irinotecan is an important chemotherapeutic agent used in the treatment of colorectal cancer. However, standard irinotecan is typically cleared from the body within a few hours of dosing, resulting in a lower tumor exposure to the active metabolite that may limit its efficacy. Clinical and preclinical studies with NKTR-102 have been shown to increase the life and exposure profiles relative to

irinotecan, resulting in significant anti-tumor activity. For more information, visit www.nektar.com.

Prior to Nektar, Dr. Masuoka was Vice President of Clinical Development at Five Prime Therapeutics where she led the advancement of a novel protein from research into clinical testing. Prior to that, she held senior leadership positions at Chiron and Berlex. At Chiron, Dr. Masuoka was Director of Clinical Development, Oncology, and led the efforts for a novel small molecule for gastrointestinal malignancies and an anti-CD40 antibody for hematologic malignancies. While at Berlex, she led efforts on Betaseron® and a novel small molecule drug for multiple sclerosis. Dr. Masuoka received her M.D. from the University of California, Davis, completed a Fellowship at Yale University and is board certified in Neurology.

All This Science But Who Pays for It?
Matthew Zubiller, Vice President, Advanced Diagnostic Management, McKesson

Mr. Zubiller is Vice President and General Manager of McKesson's Advanced Diagnostics Management business (www.mckesson.com/diagnostics). His team leads initiatives that advance McKesson's role in the realm of personalized medicine, genetics and molecular diagnostics. Before joining McKesson, Mr. Zubiller worked for a global strategy consulting firm in London, co-founded a spin-off from a leading Enterprise Resource Planning software and services vendor, and then founded and sold a boutique consulting practice working with early stage technology companies, entrepreneurs and venture capitalists in the U.S., U.K., and India. Matt holds an MBA from London Business School, a management of technology degree from the Berkeley College of Engineering and the Haas Business School, and was recently named to Healthspottr's "Future Health 100" as a healthcare innovations leader.

Consolidating the Global Effort in Personalized Medicine
Dr. Stephen Friend, Founder, Sage Bionetworks

Dr. Friend is currently the President and CEO of Sage Bionetworks. He was previously a Senior Vice President at Merck & Co., Inc. where he led Merck's Basic Cancer Research efforts. In 2005, he led the Advanced Technologies and Oncology groups to firmly establish molecular profiling activities throughout Merck's laboratories around the world, as well as to coordinate oncology programs from basic research through Phase IIA clinical trials.

Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center's Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.